• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>GlaxoSmithKline PLC

GlaxoSmithKline PLC

GlaxoSmithKline PLC ADR GSK 3 Star

Last Price$46.79Day Change (%)-1.12%
Open Price$46.67Day Change ($)-0.53
Day Range46.66–46.8652-Week Range46.01–56.73

As of Tue 09/23/2014 08:43 AM EST | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Germany's Merck to Buy Sigma-Aldrich for $17 Billion--3rd Update

    Germany's Merck to Buy Sigma-Aldrich for $17 Billion--3rd Update

  2. ADR Shares End Lower; GlaxoSmithKline, SAP Shares Trade Actively

    ADR Shares End Lower; GlaxoSmithKline, SAP Shares Trade Actively

  3. MARKET SNAPSHOT: U.S. Stocks: Futures Higher As Fed Rate View Holds

    MARKET SNAPSHOT: U.S. Stocks: Futures Higher As Fed Rate View Holds

  4. UPDATE: U.S. stocks: Futures higher as Fed rate view holds

    UPDATE: U.S. stocks: Futures higher as Fed rate view holds

  5. UPDATE: U.S. stocks: Futures higher as Fed rate view holds

    UPDATE: U.S. stocks: Futures higher as Fed rate view holds

  6. U.S. stocks: Futures higher as Fed rate view holds

    U.S. stocks: Futures higher as Fed rate view holds

  7. MARKET SNAPSHOT: U.S. Stocks: Futures Higher As Fed Rate View Holds

    MARKET SNAPSHOT: U.S. Stocks: Futures Higher As Fed Rate View Holds

  8. China fines GSK $490 million, sentences exec over bribery

    China fines GSK $490 million, sentences exec over bribery

  9. Research and Markets: Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles

    Research and Markets: Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - 13 Companies & 24 Drug Profiles

  10. Research and Markets: Global Acute Respiratory Distress Syndrome Therapeutics Pipeline Review, H2 2014 - 10 Companies & 24 Drug Profiles

    Research and Markets: Global Acute Respiratory Distress Syndrome Therapeutics Pipeline Review, H2 2014 - 10 Companies & 24 Drug Profiles

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.